Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: August 30, 2022 Report Code: GDGMDHC22301IDB-ST

Select Item

Idiopathic Pulmonary Fibrosis (IPF) symptoms include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness, and weight loss. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents, and anticoagulants.

The IPF pipeline drugs market research report provides an analysis of the IPF drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for IPF and features dormant and discontinued projects.

Key Targets of the IPF Pipeline Drugs Market

Some of the targets of the IPF pipeline drugs market are Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2, Rho Associated Protein Kinase 2, Lysophosphatidic Acid Receptor 1, Transforming Growth Factor Beta, Transforming Growth Factor Beta 1, Epithelial Discoidin Domain Containing Receptor 1, Macrophage Colony Stimulating Factor 1 Receptor, and Phosphatidylinositol 3 Kinase among others.

IPF Pipeline Drugs Market, by Key Targets

IPF Pipeline Drugs Market, by Key Targets

For more insights on key targets, download a free report sample

Key Mechanisms of Action in the IPF Pipeline Drugs Market

The key mechanisms of action of the IPF pipeline drugs market are Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 Inhibitor, Rho Associated Protein Kinase 2 Inhibitor, Lysophosphatidic Acid Receptor 1 Antagonist, Transforming Growth Factor Beta 1 Inhibitor, Transforming Growth Factor Beta Inhibitor, and Epithelial Discoidin Domain Containing Receptor 1 Inhibitor among others.

IPF Pipeline Drugs Market, by Key Mechanisms of Action

IPF Pipeline Drugs Market, by Key Mechanisms of Action

For more insights on key mechanisms of action, download a free report sample

Key Routes of Administration in the IPF Pipeline Drugs Market

The routes of administration in the IPF pipeline drugs market are oral, intravenous, inhalational, subcutaneous, parenteral, topical, subconjunctival, intravenous drip, intravitreal, and nasal among others.

IPF Pipeline Drugs Market, by Routes of Administration

IPF Pipeline Drugs Market, by Routes of Administration

For more insights on routes of administration, download a free report sample

Key Molecule Types in the IPF Pipeline Drugs Market

The molecule types in the IPF pipeline drugs market are Small Molecule, Monoclonal Antibody, Cell Therapy, Antisense Oligonucleotide, Biologic, Peptide, Recombinant Protein and Antisense RNAi Oligonucleotide among others.

IPF Pipeline Drugs Market, by Molecule Types

IPF Pipeline Drugs Market, by Molecule Types

For more insights on molecule type, download a free report sample

Key Companies in the IPF Pipeline Drugs Market

Some of the key companies in the IPF pipeline drugs market are AstraZeneca Plc, BreStem Therapeutics, Inc, Bristol-Myers Squibb Co, Galapagos NV, HEC Pharma Co Ltd, Algernon Pharmaceuticals Inc, and Angion Biomedica Corp among others.

IPF Pipeline Drugs Market, by Companies

IPF Pipeline Drugs Market, by Companies

For more insights on companies, download a free report sample

IPF Pipeline Drugs Market Report Overview

Key Targets Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2, Rho Associated Protein Kinase 2, Lysophosphatidic Acid Receptor 1, Transforming Growth Factor Beta, Transforming Growth Factor Beta 1, Epithelial Discoidin Domain Containing Receptor 1, Macrophage Colony Stimulating Factor 1 Receptor, and Phosphatidylinositol 3 Kinase
Key Mechanisms of Action Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 Inhibitor, Rho Associated Protein Kinase 2 Inhibitor, Lysophosphatidic Acid Receptor 1 Antagonist, Transforming Growth Factor Beta 1 Inhibitor, Transforming Growth Factor Beta Inhibitor, and Epithelial Discoidin Domain Containing Receptor 1 Inhibitor
Key Routes of Administration Oral, Intravenous, Inhalational, Subcutaneous, Parenteral, Topical, Subconjunctival, Intravenous Drip, Intravitreal, and Nasal
Key Molecule Types Small Molecule, Monoclonal Antibody, Cell Therapy, Antisense Oligonucleotide, Biologic, Peptide, Recombinant Protein and Antisense RNAi Oligonucleotide
Key Companies AstraZeneca Plc, BreStem Therapeutics, Inc, Bristol-Myers Squibb Co, Galapagos NV, HEC Pharma Co Ltd, Algernon Pharmaceuticals Inc, and Angion Biomedica Corp

Scope 

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

3+2 Pharma LLC
9 Meters Biopharma Inc
AbbVie Inc
Accendatech Co Ltd
Accro Bioscience Suzhou Co Ltd
AdAlta Ltd
Aeon Respire Inc
Afimmune Biopharma Ltd
AgomAb Therapeutics NV
Akeso Inc
Algernon Pharmaceuticals Inc
Altavant Sciences Inc
Altay Therapeutics Inc
Aluda Pharmaceuticals Inc
Alveolus Bio Inc
Amgen Inc
AmMax Bio Inc
Amniotics AB
Amplia Therapeutics Ltd
AnaMar AB
Angion Biomedica Corp
Annji Pharmaceutical Co Ltd
Apaxen
APIE Therapeutics Inc
Aqua Therapeutics Co Ltd
Aqualung Therapeutics Corp
Aria Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Arroyo BioSciences LLC
Asahi Kasei Pharma Corp
AstraZeneca Plc
Atrapos Therapeutics LLC
AusBio Ltd
Avalyn Pharma Inc
BerGenBio ASA
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Bonac Corp
BreStem Therapeutics Inc
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
CellCure
CellionBioMed Inc
Celon Pharma SA
Centessa Pharmaceuticals Plc
Certa Therapeutics Pty Ltd
Chemomab Therapeutics Ltd
Chengdu Huitai Biomedicine Co Ltd
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corporation
Citryll BV
CohBar Inc
Collaborations Pharmaceuticals Inc
CrystalGenomics Inc
CSL Ltd
Cynata Therapeutics Ltd
Cytonus Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
DICE Therapeutics Inc
DisperSol Technologies LLC
e-Therapeutics Plc
EffectorBio Inc
Elixiron Immunotherapeutics Inc
EmphyCorp Inc
Endogena Therapeutics Inc
Epigen Biosciences Inc
Epitracker Inc
ethris GmbH
Excalibur Pharmaceuticals Inc
Exorphia Co Ltd
Eyestem Research Pvt Ltd
F. Hoffmann-La Roche Ltd
Faknostics LLC
FibroGen Inc
FibroStatin SL
Foresee Pharmaceuticals Co Ltd
Galapagos NV
Galecto Inc
Genetic Intelligence Inc
Genflow Biosciences Srl
GenKyoTex SA
Genome Protection Inc
Genosco Inc
Global Blood Therapeutics Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
H4Orphan Pharma
Halo Therapeutics Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hanmi Pharmaceuticals Co Ltd
HCW Biologics Inc
HEC Pharma Co Ltd
Heilongjiang ZBD Pharmaceutical Co Ltd
Horizon Therapeutics Plc
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc
iBio Inc
Imago Pharmaceuticals Inc
Immunomet Therapeutics Inc
inCerebro Co Ltd
Innovative Precision Medicine Group
InSilico Medicine
INVENT Pharmaceuticals Inc
Inventiva SA
iOnctura SA
Ionis Pharmaceuticals Inc
Isarna Therapeutics GmbH
Iterion Therapeutics Inc
J2H Biotech
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
Kadmon Holdings Inc
KBP Biosciences Co Ltd
Kinarus AG
Kither Biotech Srl
Kyorin Pharmaceutical Co Ltd
Lamellar Biomedical Ltd
Lanier Biotherapeutics Inc
Lassen Therapeutics 1 Inc
Lignamed LLC
Lispiro LLC
LTT Bio-Pharma Co Ltd
Lung Therapeutics Inc
MannKind Corp
Max Biopharma Inc
MD Healthcare Inc
MDI Therapeutics Inc
Medibiofarma SL
Metagone Biotech Inc
Metera Pharmaceuticals Inc
Mission Therapeutics Ltd
MitoImmune Therapeutics Inc
Molecure SA
MyMD Pharmaceuticals, Inc
National Institutes of Pharmaceutical R&D Co Ltd
NB Health Laboratory Co Ltd
New Amsterdam Sciences Inc
Nexel Co Ltd
Nextgen Bioscience
Nogra Pharma Ltd
Novartis AG
Novo Nordisk AS
NovoMedix LLC
Nuformix Plc
Oasis Pharmaceuticals LLC
Ocean Biomedical Inc
Oleolive LLC
OliX Pharmaceuticals Inc
Omega Therapeutics Inc
Onegene Biotechnology Inc
Opsidio LLC
OptiKira LLC
OROX BioSciences Inc
Oxcia AB
Palo BioFarma SL
Panorama Researchama Research
Pharmaxis Ltd
Pieris Pharmaceuticals Inc
Pliant Therapeutics Inc
Prasan Pharmaceutical Consultants LLC
PRISM Pharma Co Ltd
Pulmatrix Inc
Pulmongene Ltd
PulmoSIM Therapeutics
Puretech Health Plc
RDS2 Solutions Inc
Redx Pharma Plc
Regenasome Pty Ltd
Rejuvenation Technologies Inc
Resolute Pharma Inc
Reviva Pharmaceuticals Inc
Ribomic Inc
Rohto Pharmaceutical Co Ltd
Rubedo Life Sciences Inc
Saje Pharma LLC
Saniona AB
Segue Therapeutics LLC
Senolytic Therapeutics Inc
Shanghai Ark Biopharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Laifu Medical Technology Co Ltd
Shanghai Life Science & Technology
Shaperon Inc
Shijiazhuang Sagacity New Drug Development Co Ltd
Shionogi & Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
SignalRx Pharmaceuticals Inc
Silurian Pharmaceuticals Inc
Sino Biopharmaceutical Ltd
SK Chemicals Co Ltd
Structure Therapeutics Inc
Surrozen Inc
Suzhou Regend Therapeutics Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
SynDevRx Inc
Taiho Pharmaceutical Co Ltd
Taiwan Liposome Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
Telomere Therapeutics
Tetragenetics Inc
Thirona Bio Inc
Tiziana Life Sciences Plc
Topadur Pharma AG
TRACON Pharmaceuticals Inc
Translate Bio Inc
Tvardi Therapeutics Inc
Ube Industries Ltd
United Therapeutics Corp
Unity Biotechnology Inc
Vectus Biosystems Ltd
Velvio GmbH
Verona Pharma Plc
Vicore Pharma AB
Viridian Therapeutics Inc
Wuhan LL Science and Technology Development Co Ltd
Xfibra Inc
Yungjin Pharm Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Idiopathic Pulmonary Fibrosis – Overview

Idiopathic Pulmonary Fibrosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Idiopathic Pulmonary Fibrosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Idiopathic Pulmonary Fibrosis – Companies Involved in Therapeutics Development

Idiopathic Pulmonary Fibrosis – Drug Profiles

Idiopathic Pulmonary Fibrosis – Dormant Projects

Idiopathic Pulmonary Fibrosis – Discontinued Products

Idiopathic Pulmonary Fibrosis – Product Development Milestones

Featured News & Press Releases

Oct 05, 2022: Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn

Sep 06, 2022: NXP002 data to be presented at the 2022 European Respiratory Society Congress

Aug 17, 2022: Arrowhead files for regulatory clearance to initiate phase 1/2a study of ARO-MMP7 for idiopathic pulmonary fibrosis

Aug 17, 2022: Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress

Aug 15, 2022: Bridge Biotherapeutics receives FDA authorization to proceed with phase 2 study of BBT-877

Aug 10, 2022: Nuformix : NXP002 successful completion of tolerability studies

Aug 03, 2022: Algernon Pharmaceuticals invited to present phase 2 IPF and chronic cough study data at 9th American Cough Conference

Aug 02, 2022: Elixiron Immunotherapeutics announces orphan drug designation granted to CSF-1R inhibitor, EI-1071 for the treatment of idiopathic pulmonary fibrosis

Jul 28, 2022: Algernon Pharmaceuticals reports additional positive data from its phase 2 study of Ifenprodil for IPF and chronic cough

Jul 20, 2022: Daewoong Pharmaceutical gets first Korean US FDA fast-track for new idiopathic pulmonary fibrosis drug

Jul 11, 2022: Pliant reports positive data from Phase IIa idiopathic pulmonary fibrosis trial

Jul 04, 2022: AD-214 program modified to maximise partnering options, extends cash runway

Jun 30, 2022: PureTech initiates late-stage clinical study of wholly-owned candidate LYT-100 (deupirfenidone) in IPF

Jun 27, 2022: Nuformix : NXP002 Update

Jun 24, 2022: Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Idiopathic Pulmonary Fibrosis – Dormant Projects, 2022

Idiopathic Pulmonary Fibrosis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Idiopathic Pulmonary Fibrosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the targets of the IPF pipeline drugs market?

    Some of the targets of the IPF pipeline drugs market are Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2, Rho Associated Protein Kinase 2, Lysophosphatidic Acid Receptor 1, Transforming Growth Factor Beta, Transforming Growth Factor Beta 1, Epithelial Discoidin Domain Containing Receptor 1, Macrophage Colony Stimulating Factor 1 Receptor, and Phosphatidylinositol 3 Kinase among others.

  • What are the mechanisms of action of the IPF pipeline drugs market?

    The key mechanism of action of the IPF pipeline drugs market are Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 Inhibitor, Rho Associated Protein Kinase 2 Inhibitor, Lysophosphatidic Acid Receptor 1 Antagonist, Transforming Growth Factor Beta 1 Inhibitor, Transforming Growth Factor Beta Inhibitor, and Epithelial Discoidin Domain Containing Receptor 1 Inhibitor among others.

  • What are the routes of administration in the IPF pipeline drugs market?

    The routes of administration in the IPF pipeline drugs market are oral, intravenous, inhalational, subcutaneous, parenteral, topical, subconjunctival, intravenous drip, intravitreal, and nasal among others.

  • What are the molecule types in the IPF pipeline drugs market?

    The molecule types in the IPF pipeline drugs market are Small Molecule, Monoclonal Antibody, Cell Therapy, Antisense Oligonucleotide, Biologic, Peptide, Recombinant Protein and Antisense RNAi Oligonucleotide among others.

  • Which are the key companies in the IPF pipeline drugs market?

    Some of the key companies in the IPF pipeline drugs market are AstraZeneca Plc, BreStem Therapeutics, Inc, Bristol-Myers Squibb Co, Galapagos NV, HEC Pharma Co Ltd, Algernon Pharmaceuticals Inc, and Angion Biomedica Corp among others.

Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Respiratory reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Generic Drugs - Physician Perspective - Thematic Intelligence
$1,495 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more